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Thrombospondin Cooperates with CD36 and the Vitronectin Receptor in
Macrophage Recognition of Neutrophils Undergoing Apoptosis
John Savill, Nancy Hogg,* Yi Ren, and Christopher Haslett
Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, Du Cane Road, London W12 ONN, United
Kingdom; and *Macrophage Laboratory, Imperial Cancer Research Fund, Lincoln's Inn Fields, London WC2A 3PX, United Kingdom
Abstract
We have investigated the cell surface recognition mechanisms
used by human monocyte-derived macrophages (MO ) in phago-
cytosis of intact aging human neutrophils (PMNs) undergoing
apoptosis. This study shows that the adhesive protein thrombo-
spondin (TSP) was present in the interaction, both associated
with the MO surface and in solution at a mean concentration of
0.59 ,g/ml. The interaction was inhibited by treatment ofMO
(but not aged PMN) with cycloheximide, but could be "res-
cued" by replenishment with exogenous TSP. Under control
conditions, MO recognition of aged PMNs was specifically po-
tentiated by purified platelet TSP at 5 ,g/ml, present either in
the interaction or if preincubated with either cell type, suggest-
ing thatTSP might act as a "molecular bridge" between the two
cell types. In support, both aged PMN and MO were found to
adhere to TSP, and phagocytosis of aged PMN was specifically
inhibited by (a) excess soluble TSP; (b) antibodies to TSP that
also inhibit TSP-mediated adhesion to aged PMN; and (c)
down-regulation of M4 receptors for TSP by plating MO on
TSP-coated surfaces. Furthermore, inhibition with mAbs /
Arg-Gly-Asp-Ser peptide of the candidate MO receptors for
TSP, CD36, and a,83 exerted synergistic effects on both MO
recognition of aged PMN and MO adhesion to TSP, indicating
that "two point" adhesion of TSP to these MO structures is
involved in phagocytosis of aged PMN. Our findings indicate
newly defined roles for TSP and CD36 in phagocytic clearance
of senescent neutrophils, which may limit inflammatory tissue
injury and promote resolution. (J. Clin. Invest. 1992.90:1513-
1522.) Key words: adhesion* integrins * resolution * inflamma-
tion * leukocytes
Introduction
In inflammation, neutrophils and their contents can injure tis-
sue and may generate chemotactic factors with potential to
amplify leukocyte infiltration ( 1, 2, 3). Safe removal ofneutro-
phils from the perturbed site is, therefore, a prerequisite ofreso-
lution ofinflammation. Uptake of intact senescent neutrophils
by macrophages at resolving inflamed sites was recognized
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many years ago (4), and, for example, has been shown to be the
dominant mechanism of neutrophil clearance from the experi-
mentally inflamed peritoneum (5, 6). However, only recently
have the mechanisms involved in this cellular interaction come
under study. Building on earlier work (7), we showed that
human neutrophils isolated from blood or inflamed sites and
aged for - 24 h in culture undergo morphological and bio-
chemical changes typical of programmed cell death (apopto-
sis), a process characterized by evidence of endogenous endo-
nuclease activation ( 8-1 1 ). Apoptosis in aging neutrophils de-
termined recognition and uptake ofthe intact senescent cell by
human monocyte-derived macrophages and human macro-
phages isolated from inflamed sites in vivo. As apoptotic neu-
trophils retained their membrane integrity and did not release
toxic contents, these processes appear to represent a mecha-
nism for disposal of intact senescent neutrophils in a manner
likely to limit their toxic potential (8). In the present study, we
examine the cell surface mechanisms used by macrophages in
recognition of apoptotic neutrophils.
Previously, we found that the macrophage aCf33 integrin, or
vitronectin receptor (VnR),' has a role in recognition of aged
neutrophils (12). The interaction depended on the divalent
cations Ca"+ and Mg", and was specifically inhibited by (a)
the tetrapeptide Arg-Gly-Asp-Ser (RGDS) at 1 mM, but not
the control peptide Arg-Gly-Glu-Ser (RGES); (b) by soluble
and substrate-bound fibronectin (Fn) and vitronectin (Vn),
but not fibrinogen or type IV collagen, which also bear the
RGD recognition sequence; and (c) by monoclonal antibodies
to both subunits of the aCf33 integrin, which is expressed by the
MO not the apoptotic neutrophil ( 12-14). It was concluded
that the VnR played a direct role in the recognition mecha-
nism, a new function for this receptor in addition to its known
roles in cell anchorage to matrix proteins ( 13 ). However, MO
recognition ofaged neutrophils was also directly modulated by
pH and specifically inhibited by millimolar concentrations of
aminosugars and basic aminoacids in a charge-dependent fash-
ion (15), and such observations were not explained by the
molecular interactions of the MO VnR.
Cationic amino sugars and basic amino acids also inhibit
the trypsin-sensitive "lectin-like" property displayed by acti-
vated platelets in agglutination of fixed platelets and fixed tryp-
sinized erythrocytes ( 16). Subsequently, the activated platelet
"lectin" was shown to be thrombospondin (TSP) ( 17). TSP is
a "multifunctional" trimeric adhesive molecule of - 450 kD
capable of binding to a wide range of macromolecules and
many cell types ( 18-22). TSP has been implicated as a "molec-
1. Abbreviations used in this paper: EIgG, ox red erythrocytes opson-
ized with rabbit IgG; Fn, fibronectin; MO, monocyte-derived macro-
phages; RGDS, tetrapeptide Arg-Gly-Asp-Ser; RGES, control peptide
Arg-Gly-Glu-Ser; TSP, thrombospondin; Vn, vitronectin; VnR, av,3
vitronectin receptor.
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ular bridge" mediating adhesive interactions between activated
platelets and other cells, including erythrocytes and monocyte/
macrophages (23-25). However, the mechanisms by which
TSP binds to cells are incompletely understood and potentially
complex, since there is evidence that a number of cell surface
molecules may be involved, including sulfatides, proteoglycans
and proteins, including al33 and the 88-kD monomer GPIV/
CD36 (23, 25-28). Although first isolated from the a-granule
of the platelet, TSP has been found to be synthesized and se-
creted by a wide range of cell types in culture (20-22), includ-
ing both macrophages and neutrophils (29, 30), and there is
evidence that each cell type may bear receptors for TSP (28,
31-34). Indeed, macrophages may have TSP associated with
their surfaces (33, 34). Furthermore, TSP has been shown to
be a transient component of the inflammatory extracellular
matrix of healing wounds present at the time in which neutro-
phils are removed from the tissue (35), and has also been dem-
onstrated in lavage fluid from inflamed lungs (36). Conse-
quently, in the present study, we sought evidence that TSP and
TSP-binding structures were involved in MO recognition of
aged neutrophils. Our data indicate that thrombospondin can
act as a "molecular bridge" between the aged neutrophil and
the MO, where the molecule appears to bind to both GPIV/
CD36 and the aCl33 integrin, indicating hitherto unrecognized
functions for both TSP and GPIV/CD36.
Methods
Materials
All chemicals were from Sigma Chemical Co. (St. Louis, MO), unless
otherwise indicated; culture media (HBSS, Iscove's DME) and supple-
ments ( 100 U/liter of penicillin and streptomycin) were from Gibco
Laboratories (Grand Island, NY); and sterile tissue culture plasticware
were from Falcon Plastics (Cockeysville, MD).
Peptides and proteins
The tetrapeptides RGDS and RGES were obtained from Peninsula
Laboratories, Inc., (Belmont, CA), human albumin (fraction V) was
from Sigma and fibronectin from Calbiochem Corp. (San Diego, CA).
TSP was purified from thrombin-stimulated human platelets by hepa-
rin-Sepharose affinity chromatography followed by "sizing" on a 4B-
Sepharose column by standard methods (18). Particular care was
taken to use only those fractions in which the protein ran as a single
band on reducing SDS-PAGE assessed by silver staining and immuno-
blotting with amAb specific forTSP (TSP-B7; Sigma). Contamination
with Vn was quantified at < 0.1% by specific ELISA (data courtesy of
Dr. W. Bennett). Proteins and peptides were dialyzed in HBSS be-
fore use.
Monoclonal antibodies
Dr. V. Dixit kindly provided a panel of IgG1 mAbs specific for TSP,
namely C6.7, A6. 1, A2.5, and D4.6, each of which has been shown to
inhibit various TSP-related phenomena (37-39); Drs R. Nachman
and R. Silverstein provided the TSP-specific mAb 11.2 (24). CD36
mAbs were SM4, an IgM (40, 41) and ClMegl, an IgG, (40) (a gift
from Dr. G. Pilkington). The aC(3 mAb was 23C6 (42) (a gift from Dr.
M. Horton). Control mAbs were P3 (43) an irrelevant IgG, (a gift
from Dr. P. Morganelli), P112 (44) an IgM that recognizes the GPII-
bIIIa complex, 28 (40, 44) an IgM recognizing CDI 5, and OX7 (Sero-
tec, Banbury, Oxon, U.K.), an IgG, that recognizes Thyl. 1. Antibodies
were used as purified immunoglobulin (23C6, 11.2,P3) or ascites
(C6.7, A2.5, A6. 1, D4.6, SMU, ClMegl, 23C6, P112, OX7) diluted in
HBSS as described.
Cells
Neutrophils (> 98% pure May-Giemsa) were isolated from fresh, ci-
trated normal human blood by dextran sedimentation and plasma-Per-
coll (Pharmacia Fine Chemicals, Piscataway, NJ), aged in tissue cul-
ture for - 28 h in Iscove's DME with 10% autologous platelet-rich,
plasma-derived serum, and apoptosis verified by oil-immersion light
microscopy of May-Giemsa stained cytopreps, exactly as previously
described (8, 15). Human monocyte-derived macrophages (M+) were
prepared by standard methods from adherent PBMC by culture for 5-7
d in 24-well plates in Iscove's medium with 10% autologous serum as
described (45, 8). No contaminating platelets attached to M4 could be
detected either by careful microscopic inspection or by immunofluores-
cence using mAb P112 specific for platelet GPIIbIIIa. For demonstra-
tion ofcell surface TSP by flow cytometry (see below), monocytes were
purified by elutriation (46) and matured in nonadherent culture in
teflon-lined vessels for 5-7 d. Ox erythrocytes, opsonized with polyclo-
nal rabbit anti-ox IgG (gift from Dr. D. Grennan) were prepared as
described ( 15).
Assay and localization ofTSP
TSP in solution in medium was assayed by ELISA exactly as described
(34), using rabbit polyclonal immunoglobulin specific for TSP
( 1:5,000 in PBS; a gift from Dr. N. Hunter); this assay was sensitive to
a lower limit of 50 ng/ml. TSP was sought on the surface of cultured
MO and neutrophils by immunofluorescence flow cytometry, using a
standard protocol of labeling and three washes at the end of each step,
as described ( 12). Binding of C6.7 ( 1:100 dilution in PBS/0.1% BSA)
was compared with an identical dilution of OX7 ascites as a control,
detected using FITC-conjugated Fab'2 sheep anti-mouse immunoglobu-
lin antibody ( 1:30; Sigma). Aged neutrophils were studied by the same
techniques.
Interaction assays
This microscopically quantified phagocytic assay has been described
and illustrated in detail before (8, 15). Briefly, aged neutrophils were
washed once in HBSS and suspended in HBSS. 2.5 X 106 aged PMN in
300 M1 HBSS were added to each washed well ofMO and incubated at
37°C in a 5% CO2 incubator at pH 7.4. In view ofour previous findings
of the importance ofpH ( 15), particular care was taken to ensure that
the pH ofHBSS was adjusted and maintained correctly. At the end of
the interaction period, the wells were washed in saline at 4°C, fixed
with 2% glutaraldehyde in PBS, stained for myeloperoxidase and then
the proportion of MO ingesting neutrophils counted by inverted light
microscopy, exactly as described (8, 15). In keeping with our previous
description ofthis assay, the proportion ofM4 recognizing aged neutro-
phils varied between donors, so to compare data between experiments
in which MO from different donors were used, data are presented as
percentage of the mean of control in each ofthe relevant experiments,
as described ( 15). However, the absolute percentage ofM4 recognizing
aged neutrophils in the relevant series of experiments is also given in
the figure legend. Uptake of opsonized ox erythrocytes (EIgG) was
determined by similar means, as described ( 15). In all experiments,
> 95% ofMk took up EIgG.
Effects ofproteins in solution. TSP or human albumin were in-
cluded in the interaction medium at the desired concentration in HBSS
and interactions performed in HBSS alone served as control. In prein-
cubation experiments, proteins at S ug/ml were incubatedwith washed
aged neutrophils or M4 at 37°C for 15 min (HBSS alone being used in
"control" experiments), washed and then incubated with untreated
MO or neutrophils as appropriate under the standard conditions ofthe
assay.
Effects ofmonoclonal antibodies. These were determined as previ-
ously described (12, 15). Briefly, adherent MO cultured in 24-well
plates were washed, 300 Ml ofmAb at desired concentration in HBSS
(or HBSS alone as a control) was added to each well. The plates were
incubated for 15 min at 4°C, followed by addition of 2.5 x 106 washed
aged neutrophils (or EIgG) in 100 Al ofwarm HBSS and then interac-
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tion for 30 min under standard conditions. In no experiment did mAbs
affect cell viability as assessed by trypan blue exclusion. In one series of
experiments designed to determine the cellular localization ofthe effect
ofmAb SMO either aged neutrophils (at 2.5 X 106/ml) or adherentMO
were preincubated with mAb SM40 ( 1:25 dilution) for 30 min at 4VC,
before washing twice in HBSS and interaction with untreated cells of
the opposite type under standard conditions. These effects were com-
pared with those of presence ofmAb at the same concentration in the
interaction medium, without the usual 15-min M4$ preincubation.
It should be noted that in previous work, a large number of murine
mAbs of varying isotype have been examined in this assay in the form
of intact Ig (either purified or as hybridoma ascites) ( 12, 15). Except
for mAbs to afl3, none has inhibited, including mAbs to MO and
neutrophil surface structures, indicating that nonspecific "steric" ef-
fects are unlikely to be the reason for the blocking effects ofmAb in this
system. Furthermore, no mAb (including those used in this study)
have promoted M40 phagocytosis of freshly isolated neutrophils in a
manner suggesting that murine mAbs might opsonize neutrophils for
M4, thus complicating the interpretation of these data.
Effects ofplating M4 on tissue culture surfaces treated with pro-
teins. TSP was adsorbed to the bottom of tissue culture-treated wells by
standard methods (47-49, 27). 50 Al of a solution of TSP or human
albumin at 80 tg/ml in HBSS was incubated in each well of a 96-well
flat-bottomed Falcon tissue culture plate for 2 h at room temperature
and washed twice in HBSS and "control" wells were incubated with
HBSS alone. Mature M4 were "mobilized" from adherent culture by
methods shown by immunofluorescence flow cytometry to "strip"
them of surface-associated TSP (data not shown) to facilitate modula-
tion ofreceptors by substrate-bound proteins. ThusMO were incubated
with 5 mM EDTA in HBSS with no Ca"+ or Mg"+ for 15 min at 4VC,
detached from the plate by pipetting, washed twice in warm HBSS,
suspended at 5 X 105/ml and 50 ,l of suspension added to each well.
The cells, which formed a "subconfluent" monolayer, underwent re-
ceptor modulation (or not) during incubation at 370C for 30 min. The
medium was then aspirated and replaced with 100 Ml ofa suspension of
aged neutrophils in HBSS at 2.5 x 106/ml, or EIgG at 5 x 106/ml for a
30-min interaction. Counting of M40 by inverted microscopy showed
that < 10% of Mk originally added to the well were lost during these
steps, indicating that adherent MO were not a subpopulation.
Assay ofadhesion ofaged neutrophils to latex beads
In preliminary experiments, apoptotic PMN did not spread on tissue
culture-treated surfaces or hemocytometer glass, remaining spherical
and resisting mechanical displacement only weakly (Whyte, M.K.B.,
J.S. Savill, and C. Haslett; unpublished data). Consequently, we sought
adhesion to protein-coated 0.995-,Mm latex beads (LBl 1; Sigma) by
minor modifications of standard methods (50, 51 ), since this does not
require neutrophil spreading. A 300-Ml aliquot of a 10% stock suspen-
sion of latex beads was added to a 1.5-ml polythene Eppendorf tube,
pelleted and washed three times in 0.9% saline, and then incubated
with either TSP or human Fn (Calbiochem) at 100 gg/ml in 0.9%
saline with Tris HCl 20 mM, pH 7.4, for 10 min at room temperature.
The bead suspension was then sonicated with a probe sonicator (60 W)
to break up microclumps, centrifuged and resuspended in 10 mg/ml
human albumin in HBSS, then incubated for a further 10 min at room
temperature. Beads were pelleted and washed three times in HBSS
before resuspension in 500 Ml HBSS; i.e., a 6% suspension. TSP coating
was confirmed by positive indirect immunofluorescence with mAb
11.2 at 2.5 Ag/ml and negative staining with irrelevant mAb P3 at the
same concentration. Aged neutrophils were washed and resuspended at
50 X 106/ml in HBSS, and 225 ,l were added to each test tube (Falcon
LP3 polythene tubes). In some experiments TSP mAbs C6.7, A2.5,
A6. 1, and D4.6 were included in the medium at a dilution of 1 in 25 of
ascites. 25 ml offreshly prepared 6% beads was added to the cell suspen-
sion to achieve a final bead concentration of 0.6%, and the tube was
shaken in a 370C water bath at 110 beats/min for 15 min, supple-
mented by manual agitation at 7 min. In preliminary experiments
under these conditions, TSP mAbs at the concentration described
above did not aggregate either beads or aged neutrophils alone, indicat-
ing that inhibitory effects on bead binding were unlikely to be by such
"artefactual" mechanisms that might have reduced the area of inter-
face between beads and cells. The cells were fixed by addition of 250 M1
of2% glutaraldehyde in PBS for 10 min, and then cells separated from
unbound beads (which are oflower density) by four consecutive centrif-
ugations at 200 g for 4 min with washing in 0.9% saline, before finally
suspending beads in 250 Ml 0.9% saline and placing 50 M1 on a micro-
scope slide. The cells were inspected by oil immersion light microscopy
after placing a cover slip on the drop. 500 neutrophils were examined to
determine the percentage of cells binding beads, and then the number
of beads on each of 100 cells with beads were counted.
Assay ofMq adhesion
Established methods (47, 27), with minor modifications, were used.
Tissue culture wells in 96-well flat bottomed Falcon plates were incu-
bated with gelatin (Sigma) at 30 mg/ml in water for 2 h at 370C,
aspirated to dryness and then thoroughly dried in an oven at40C for a
further 2 h. The wells were then cooled, and 50 Ml ofTSP or Fn (Calbio-
chem) at 40 Mg/ml incubated in each well for 2 h at room temperature.
HBSS alone was used as a control. The protein suspension was then
aspirated, the wells washed twice with HBSS, and the remaining me-
dium was aspirated. Mature (5 to 7 d) MO were released from adherent
tissue culture by incubation with 5 mM EDTA in the cold, washed as
above, and suspended at 106/ml in HBSS alone or HBSS with inhibi-
tors/controls. The following inhibitors or controls were dissolved in
HBSS and used at the stated concentration, either alone or in combina-
tion: RGDS and RGES at 2.2 mM; the CD36 mAb SMO, the a!f33 mAb
23C6, and the control mAbs P112 and OX7 were all in the form of
ascitic fluid diluted 1:25. From these cell suspensions, 50-,Ml aliquots
were immediately added to protein-coated wells for 45 min at room
temperature followed by washing with 0.9% saline at 4°C. The wells
were fixed with 2% glutaraldehyde in PBS, and the number ofadherent
M4 in 10 randomly selected microscope fields counted using an in-
verted instrument with a 40X objective.
Treatment ofPMNs and Mk with cycloheximide
PMNs isolated from the same donor were cultured either under stan-
dard conditions (see above), or in conditions that were identical, ex-
cept for the presence of cycloheximide at 5 x 10-6 M. Before interac-
tion with MO under standard conditions, PMNs were washed three
times to ensure removal of cycloheximide, and viability was deter-
mined by trypan blue exclusion.
Adherent MO in 24-well plates were washed twice in HBSS, then
incubated for 6 h in 5% CO2 at 37°C in Iscove's DME as a control, or
with the same medium containing cycloheximide at 2.5 X 10-6 M. At
the end ofthis period, aliquots ofmedium were taken for measurement
of TSP concentration by ELISA (see above). The wells were then
washed three times and interacted with aged neutrophils or EIgG under
standard conditions. In some experiments, the interaction medium
contained TSP, Fn, or human albumin at 4 Mg/ml.
Results
Macrophage-synthesized TSP participates in phagocytosis of
apoptotic neutrophils. We first investigated whether TSP was
present in the standard interaction assay in which 106 MO were
coincubated with 2.5 X 106 aged PMN in 300 ,l of serum-free
medium for 30 min. In keeping with previous studies (29, 33,
34), TSP could be demonstrated in two forms. First, TSP was
detected in medium at the end of the interaction at a concen-
tration of 0.59±0.14 ,g/ml (n = 6); second, low levels ofTSP
were detected on the surface of MO by immunofluorescence
flow cytometry (Fig. 1). However, TSP could not be demon-
strated by the same techniques on the surface of aged PMN
(data not shown). Furthermore, we confirmed that the capac-
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Figure 1. Expression of
surface TSP by Mo.
Typical fluorescence
histograms from flow
cytometry of MO,
showing binding of the
IgG, anti-TSP mAb
C6.7 compared with
positive control CD36
mAb and negative con-
__-~~~-~-~-~~~- trol OXI mAb. *, anti-|
0 1=|01 000 thrombospondin; m,1190 100 00''
negative control OX1;
Mean Channel Fluorescence a, CD36.
ity ofMO to synthesize TSP was comparable to that previously
reported (29), and was over 40-fold greater than that of aged
PMN (Table I). Finally, to determine ifTSP might play a role
in Mi recognition ofaged PMN, we studied whether the inter-
action was influenced by manipulation of MO TSP synthesis
with 2.5 pM cycloheximide (Table II). This treatment mark-
edly reduced the proportion ofMO taking up aged PMNs but
did not affect uptake of EIgG. Furthermore, although cyclo-
heximide treatment may be expected to inhibit synthesis of a
wide range of proteins, "adding back" ofTSP at 4 ,g/ml (but
not Fn or albumin) to cycloheximide-inhibited MO partially
"rescued" the capacity to ingest agedPMN (Table II). Aging of
freshly isolated PMNs for 22 h in the presence of 5 mM cyclo-
heximide did not inhibit their subsequent recognition by Mo.
Thus, treated PMNs were taken up by 55.9±4.2% ofMo, com-
pared with 48.1±4.7% uptake of untreated PMNs by Mo (n
= 4). These data indicated that macrophage-synthesized TSP
plays a role in recognition of aged PMN.
Exogenous TSP modulates macrophage recognition of
apoptotic neutrophils. To examine whether TSP might be play-
ing an adhesive role in the interaction, exogenous TSP was
included in the interaction medium (Fig. 2). At concentrations
up to a peak of 5 jg/ml, added TSP increased the proportion of
M4 ingesting aged PMN. This effect was specific as albumin
(Fig. 2), Vn and Fn ( 12) at the same concentrations had no
effect, and the potentiating effect ofadded TSP was completely
inhibitable by mAb against TSP (Table III). Furthermore, TSP
did not induce Mo recognition of freshly isolated PMN. This
indicated that although Mo have TSP associated with their
surface, availability of "extra" TSP in solution appears to po-
Table I. Release ofTSP into Medium Over 6 h:
Mq Compared with AgedPMN
Cell Conditions TSP release
(pig/106 cells/6 h)
Mo Control 1.84
Mo Cycloheximide 0.14*
Aged PMN Control 0.04*
* P < 0.05 compared with TSP release by Mo under control condi-
tions. Data are means of six observations. Over the 6-h period in
each set of conditions, each cell type remained >98% viable by trypan
blue exclusion. The inhibitory effect of 2.5 AtM cycloheximide indi-
cates that the majority ofTSP released under control conditions had
been newly synthesized.
Table IL Effect on Aged Neutrophil Recognition of TreatingMk
with 2.5 ,M Cycloheximide for 6 h (n = 12):
Partial "Rescue" by TSP
Protein in Aged neutrophil
Preincubation interaction recognition EIgG uptake
(at 4 pg/ml) (% ofcontrol±SE) (% ofMO)
Control 100.0±1.26 >95%
Cycloheximide 22.2±1.05 >95%
Cycloheximide Albumin 21.5±1.22 >95%
Cycloheximide Fn 28.4±1.51 >95%
Cycloheximide TSP 61.1±2.75* >95%
In these experiments, 57.3±5.3% ofMO recognized aged neutrophils
under control conditions. * P < 0.05 relative to cycloheximide-
treated M+.
tentiate the interaction. Indeed, it appeared that the potentiat-
ing effect of 5 ug/ml TSP could be exerted at either cell surface,
since preincubation of either cell type with TSP enhanced sub-
sequent interaction under standard conditions (Fig. 3). By
contrast, at higher concentrations, TSP specifically inhibited
MO recognition of aged neutrophils; albumin had no effect at
100 ugg/ml, and TSP at this concentration did not affect My
uptake of a control particle, the IgG-opsonized erythrocyte.
Although these results suggested that the role of TSP in the
interaction might be to form a "molecular bridge" between Mq
and aged PMN, further supportive evidence would come from
demonstration that (a) TSP can support adhesion by both cell
types; and (b) inhibition of TSP binding to either cell type
inhibits the interaction.
TSP supports adhesion to apoptotic neutrophils. TSP can
mediate adhesion of cells of monocyte/macrophage lineage
(24, 27, 34). However, it has not been known whether TSP
could support adhesion by apoptotic PMNs, which would be a
O 200-
C
0
S-
c
0
gi
- 100-
0
I001
-Q 0
control 42SD °
I
(n=101
1 --I0.1 0.14 1 4i 5 10 140 100
(Thrombospondin] pg/ml
Figure 2. Effect of TSP in solution upon M4 recognition of aged
neutrophils. Each point represents mean±SE of 10 observations made
in experiments where 44.8±4.3% ofM4 recognized aged neutrophils
under control conditions. At 100 ,g/ml, TSP failed to affect MO up-
take of EIgG (open square). The dotted lines represent ± 2 SD of
159 observations ofMy recognition of aged neutrophils made under
control conditions in previous work to determine the range of in-
traexperimental variability of the assay ( 15 ).
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Table III. Specificity of Potentiating Effect of TSP on MO
Recognition ofAged Neutrophils: Specific Inhibition by Anti-TSP
mAb and Failure to Induce Recognition ofFreshly Isolated PMN
Nature of Protein in mAb in
PMN interaction interaction Recognition
(% ofcontrol±SE)
Aged TSP 5 jig/ml None 152.1±6.3
Aged TSP 5 ,g/ml Anti-TSP 53.7±6.3*
Aged TSP 5 gg/ml Control 154.3±4.6
Fresh None None 3.4±0.3
Fresh TSP 5 gg/ml None 2.8±0.4
In these experiments, 39.0±3.4% (n = 9) of MO recognized aged
PMNs under control conditions. The anti-TSP MAb was C6.7 at a
1:25 dilution of ascites; the control mAb was OX7 at the same dilution.
* P < 0.05; in separate experiments, this concentration of C6.7 was
shown not to impair M,0 ingestion of EIgG.
prerequisite for a possible "bridging" role for TSP in the inter-
action. Apoptotic PMNs adhered to latex beads coated with
TSP to a greater degree than beads coated with a Fn, used as an
adhesive protein control (Table IV). Furthermore, binding of
apoptotic PMN to TSP-coated beads was specifically inhibited
by three mAbs (C6.7, A6. 1, and A2.5) against TSP, but not by
a fourth TSP mAb, D4.6. These data indicate that TSP can
support adhesion to apoptotic PMNs.
mAbs to TSP inhibit the interaction. Surface TSP was not
detected on aged PMN (see above), indicating that if TSP
were to "bridge" macrophage to apoptotic neutrophil, then
either TSP in solution or TSP attached to the MO surface must
bind to the apoptotic neutrophil. Therefore, in the absence of
added TSP, mAbs to TSP shown to inhibit TSP binding to
LUlen
+1
-
0
u
0
ca
a
E
~0to
z
a-
-n
a
0.
150-
100-
50-
0o
T
Lii
Aib TSP
Table IV. Specific Binding of TSP-coated Beads to Aged PMN.
Specific Inhibition by Anti-TSP mAbs C6. 7, A6. 1, and A2.5,
but not by D4.6
mAb present in
Protein on bead bead-cell interaction Beads binding per cell
(mean±SE, n = 6)
TSP - 3.26±0.07
TSP C6.7 (anti-TSP) 0.43±0.08*
TSP A6. 1 (anti-TSP) 0.38±0.07*
TSP A2.5 (anti-TSP) 0.46±0.07*
TSP D4.6 (anti-TSP) 3.51±0.26
TSP P112 (control) 3.19±0.23
Fn - 0.17±0.03
Monoclonal antibodies were used as a 1:25 dilution of ascites. * P <
0.05 compared with TSP bead binding to aged PMN under control
conditions.
apoptotic PMNs might be expected to inhibit the interaction.
Specific inhibition ofM4 ingestion ofaged PMN was observed
for the three mAbs, C6.7, A6.1, and A2.5, while mAb D4.6
affected neither bead binding nor the interaction (Fig. 4). No
mAb from this panel inhibited MO ingestion of EIgG. Further-
more, mAb 3E3, which recognizes the cell-binding domain of
Fn and inhibits Fn adhesion to fibroblasts (52), failed to in-
hibit the interaction (data not shown), confirming that the
inhibitory effect ofanti-TSP mAbs was not some general prop-
erty ofmAbs against adhesive proteins. Therefore, these exper-
iments provided direct evidence in support of a "physiologi-
cal" bridging role for TSP in the interaction.
Inhibition ofmacrophage receptorsfor TSP specifically im-
pairs recognition ofapoptotic neutrophils. A further strategy to
examine whether TSP has a bridging role in the interaction
would be to manipulate MO surface adhesion receptors for
TSP. Attachment of macrophages to substrates coated with
ligand so that receptors become modulated to the underside of
the cell is a well-established method of down-regulating ligand
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Figure 3. Localization of potentiating effect of 5 jig/ml TSP. In these
experiments, where 38.1±0.7% ofMO recognized aged neutrophils
under control conditions, aged neutrophils (left panel) or M4 (center
panel) were preincubated with either TSP or human albumin (Alb),
and the effects compared with presence of the proteins at the same
concentration in the interaction (right panel). The dotted lines are
± 2 SD of control observations, as defined in Fig. 2.
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Figure 4. Monoclonal antibodies against TSP inhibit MO recognition
ofaged neutrophils of mAbs. In these experiments, mAbs were used
at a 1:25 dilution (the same concentration optimally employed in in-
hibition of TSP-coated latex bead adhesion to aged PMN). In this
series of experiments, 37.2±2.9% ofM) recognized aged PMN under
control conditions. No mAb affected EIgG uptake (closed squares).
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binding at the "free" surface ofthe cell (49, 53). For example,
we have reported that attachment of M) to surfaces treated
with Vn but not fibrinogen or type IV collagen inhibited subse-
quent recognition of aged neutrophils, in keeping with a role
for MO vitronectin receptor (ar,3) in the interaction, Conse-
quently, we examined the effect of allowing MO to modulate
surface receptors for TSP by attachment to tissue culture-
treated surfaces coated with TSP. This maneuver resulted in
strong inhibition of MO phagocytosis of aged PMNs (to
19.8±3.2% of control, n = 11, in a series ofexperiments where
57.5±1.8% ofMO took up aged PMN in control conditions).
There was no effect on ingestion of EIgG. In addition, treat-
ment of the substrate with the control protein albumin had no
effect. Therefore, this experiment appeared to confirm a role
for TSP-binding structures on the MO in recognition of aged
PMNs.
This result would be expected from the reported specificity
of a0033 for TSP (27). Nevertheless, it was also compatible with
a role for other MO TSP receptors, although our previous ob-
servation that fucoidan failed to inhibit the interaction indi-
cated that involvement of MO heparan sulfate proteoglycan
was unlikely (26, 54). However, we had not previously sought
a role for another MO adhesion receptor with specificity for
TSP, the 88-kD monomer, CD36 (25, 27). An IgM mAb to
CD36, SMO (40) inhibited MO recognition of aged neutro-
phils, but not ofEIgG (Fig. 5 A). A number of isotype control
mAbs, including mAbs binding to either cell type, had no effect
(data for one mAb shown in Fig. 5 A), indicating that the
inhibitory effect of SMO was highly unlikely to be caused by
some nonspecific "steric" effect ofIgM binding to cell surfaces.
Furthermore, an IgG, mAb to CD36, ClMegl (40), also specif-
ically inhibited phagocytosis of aged neutrophils (to
41.4±5.3% of control, n = 6; no effect on EIgG uptake was
seen). The inhibitory effect ofanti-CD36 mAbs was exerted at
the MO surface; since preincubation ofMO but not of neutro-
phils with CD36 mAbs inhibited recognition (Fig. 5 B) and
CD36 mAbs did not bind to aged neutrophils as assessed by
immunofluorescence flow cytometry (data not shown). In par-
allel experiments the SMO CD36 mAb bound specifically to
MO (Fig. 1). Therefore, these data indicate a hitherto unex-
pected role for CD36 in the interaction.
Synergistic inhibition ofthe interaction by mAbs to the vi-
tronectin receptor and CD36. Previously, we reported that
mAbs to both subunits of macrophage a143 specifically inhib-
ited MO recognition ofaged neutrophils by > 70% (12). How-
ever, in the current series of experiments a similar degree of
inhibition was observed with the CD36 mAb SM4 (Fig. 5).
These observations are compatible with the possibility that MO
CD36 and a^f,3 function together in recognition ofaged neutro-
phils. Thus, we studied the effects of a combination of anti-
CD36 and anti-av,33 mAbs, each at a concentration causing
only weak inhibition ofthe interaction when used individually.
The combination exerted a strong inhibitory effect on MO rec-
ognition of aged neutrophils which was synergistic rather than
merely additive, in keeping with a cooperative role for the two
receptors in recognition of the aged PMN (Fig. 6). This effect
was specific because combination ofeither mAb with an irrele-
vant isotype control mAb did not result in synergistic inhibi-
tion and EIgG recognition was not affected.
Macrophage adherence to TSP is mediated by a "two-
point" mechanism. Taken together, the data above suggest that
in promoting recognition ofaged neutrophils, TSP may bind to
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Figure 5. (A) Concentration-dependent inhibition by CD36 mAb
SMO on MO recognition of aged neutrophils, and (B) functional lo-
calization of inhibitory effect to M4 surface. In (A), each point rep-
resents the mean±SE of 12 observations made in experiments where
under control conditions, 39.1±2.3% of M4 recognized aged neutro-
phils. The highest concentration ofSM4 had no effect on the propor-
tion ofM) taking up EIgG (closed square). The control mAb was the
isotype matched IgM CD15 mAb, 28. The dotted lines are as defined
in Fig. 2. In (B), preincubation ofM) but not neutrophil with a 1:25
dilution ofSM4 (but not by control mAb 28) for 30 min at 4VC in-
hibited the interaction (open bars: mean±SE, n = 6) to a degree sim-
ilar to that when the mAb was included only in the interaction me-
dium. Under control conditions, 48.9±5.2% ofMO recognized aged
neutrophils.
both a,,03 and CD36 on the macrophage. Although inhibitor
studies reported by others indicate that some cell types may use
a single receptor mechanism to adhere to TSP (for example, an
RGD-inhibitable integrin [27]), there are examples of cells
which use a "two-point" mechanism (55). Neither the tetra-
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Figure 6. Synergistic inhibition ofM4 recognition of aged neutrophils
by combination ofSMO (CD36 mAb) and 23C6 (VnR mAb) n = 6.
SMO was used at a dilution of 1 in 100 ascites in HBSS, and 23C6 at
5 ttg/ml in HBSS. Each mAb induced weak but specific inhibition
of aged neutrophil recognition (open bars) and there was no effect
upon M40 uptake of EIgG (open squares). "SMo + 23C6" signifies
HBSS in which mAb SMO was present at a final dilution of 1 in 100
and 23C6 was also present at a final concentration of 5 gg/ml. The
two right hand bars are controls for this combination with mAb P3
at a final concentration of 5 jsg/ml and PI 12 ascites at a final dilution
of 1 in 100 ascites. In this series of experiments, 64.2±1.2% of M)k
recognized aged neutrophils under control conditions.
peptide RGDS nor the aVl33 mAb 23C6 inhibited MO binding
to TSP (Table V), although both inhibit macrophage recogni-
tion of aged neutrophils. Similarly, mAb to CD36 failed to
inhibit MO adhesion to TSP. However, the combination of
CD36 mAb with either af3 mAb or RGDS (but not RGES)
resulted in specific inhibition of MO to TSP. The failure of
these inhibitors to block MO binding to Fn (56) was used as a
control. These data therefore indicated that MO adhesion to
TSP-coated surfaces involved cooperative binding by both
CD36 and the RGD-inhibitable a433 vitronectin receptor inte-
grin.
Table V. Evidencefor Two-point Adhesion ofM4 via CD36
and af33 to TSP-coated Gelatin
Macrophage binding
(expressed as % ofcontrol for each adhesion)
Inhibitor(s) present in medium
during adhesion assay TSP-coated gelatin Fn-coated gelatin
None (Control) 100.0±2.6 100.0±1.9
SM0 (CD36 mAb) 97.0±7.4 100.2±4.7
RGDS 95.5±4.2 105.3±14.6
RGES 99.4±6.3 91.5±6.8
23C6 (avf3 mAb) 86.1±6.6 96.6±1.9
RGDS + SMO 17.4±4.1* 98.7±8.1
RGES + SMO 106.6±4.2 96.1±3.6
RGDS + P112 (control mAb) 95.8±2.3 103.4±8.3
SMO + 23C6 14.9±1.3* 98.1±3.6
SM4 + OX7 (control mAb) 104.7±7.3 95.8±3.7
Gelatin alone 15.5± 1.0
Monoclonal antibodies were used as a 1:25 dilution of ascites, and
tetrapeptides at 2.2 mM: When combined, the same final concentra-
tions were achieved. In these experiments (n = 9), 686±51 My ad-
hered per 10 wells to TSP-coated gelatin; 863±112 M0 adhered per
10 wells to Fn-coated gelatin. * P <0.05 compared with TSP bead
binding to aged PMN under control conditions.
Discussion
In this study, we have examined the cell surface recognition
mechanisms used by human MO in phagocytosis of intact ag-
ing human neutrophils that have undergone apoptosis, a po-
tentially "injury limiting" mode of neutrophil removal operat-
ing at inflamed sites (8). Our conclusions are that macrophage-
synthesized TSP mediates the interaction by forming a
molecular bridge between the the cell types. Furthermore, at
the MO surface the data indicate that TSP binds to both CD36
and the a433 "vitronectin" receptor.
There is evidence that TSP mediates platelet-platelet, plate-
let-erythrocyte, and monocyte-platelet adhesion by acting as a
"molecular bridge" between cells ( 17, 21, 24, 25). These inter-
actions may be potentiated by supplementing available TSP by
addition of micromolar concentrations ofexogenous TSP, and
inhibited by higher concentrations which saturate TSP-binding
sites. TSP-mediated agglutination of erythrocytes by activated
platelets has also been reported to be inhibited by millimolar
concentrations of aminosugars and basic aminoacids ( 16, 17).
This suggests that a bridging role for TSP should be sought in
MO recognition ofaged PMN, since we found that this interac-
tion was also inhibited by similar concentrations of these cat-
ionic molecules ( 15). The data obtained in this study support
the possibility that MO-synthesized TSP has a bridging role in
this phagocytic interaction. First, TSP is present, both in solu-
tion and associated with the MO surface. Second, the interac-
tion is inhibited by reducing supply of TSP in the interaction(by treating MO with cycloheximide) and "rescued" by replen-
ishing TSP supply. Third, the interaction is specifically poten-
tiated by TSP, by an effect which preincubation studies show
can be exerted at the surface of each cell type. Fourth, inhibi-
tion of TSP-mediated adhesion to aged PMN by mAbs to TSP
inhibits the interaction. Fifth, high concentrations of soluble
TSP specifically inhibit, and sixth, so does attachment of mac-
rophages to surfaces coated with TSP, a maneuver known to
down-regulate expression of adhesion receptors at the free sur-
face of the cell. Finally, supplementation of existing TSP sup-
ply by including the protein in the interaction medium at con-
centrations around 5 ,ug/ml specifically potentiated recogni-
tion. It therefore appears reasonable to conclude that TSP plays
a hitherto unexpected bridging role in MO recognition of aged
neutrophils. This represents an important new addition to the
functional repertoire of TSP, and the first defined molecular
link between the surfaces of the apoptotic PMN and the MO.
Clearly, to understand the precise role played by TSP in the
interaction, it will be necessary to define the receptors for TSP
on both cell types. At present, the mechanisms by which TSP
binds to aged neutrophils are unknown. Our current and pre-
vious data ( 12) indicate that CD36 and Avf3 play their roles at
the surface of the Mo, since in both cases the inhibitory effects
of mAbs were localized to the Mo, and neither receptor was
detectable on the surface of aged PMNs by flow cytometry.
Furthermore, our previous finding that fucoidan fails to inhibit
the interaction ( 15) suggests that neither heparan-sulfate pro-
teoglycan nor sulfatides are involved (23, 26, 54). Since freshlyisolated PMNs are not recognized by MI (8), it appears likely
that the mechanisms by which TSP binds to fresh PMN (31,
32) will prove to be different from those involved in TSP bind-
ing to aged PMN. Indeed, it is of interest that we found that the
anti-TSP mAb A2.5 inhibited the adherence ofapoptotic PMN
to TSP, while others found no effect upon the adherence of
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freshly isolated PMN to TSP (32). Ongoing work on the alter-
ations occurring in the PMN surface during apoptosis will ex-
amine possible changes in the nature of the adhesive interac-
tion with TSP.
However, the current study advances understanding of the
molecular interactions occurring at the MO surface during
phagocytosis of apoptotic cells. First, the inhibitory effects of
monoclonal antibodies to CD36 indicate a newly-identified
role in recognition of aged PMNs for this 88-kD MO surface
molecule, the physiological function of which has been ob-
scure. The degree of inhibition observed (> 80%) is compara-
ble to that reported earlier for mAbs to aC133 ( 12). This suggests
that the two receptors work in concert rather than mediating
two independent phagocytic pathways, and this possibility was
supported by synergistic inhibition ofthe interaction by combi-
nation of low concentrations of mAbs to CD36 and a,#3. Sec-
ond, although there has been controversy as to whether either
CD36 or a!f33 truly represent cellular adhesion receptors for
TSP (57-59), our studies ofMO binding to TSP indicate that
the two structures participate in a "two-point" adhesion mecha-
nism for TSP. This combination of TSP receptors is different
from those previously reported to mediate two-point adhesion
to TSP by other cell types, but is consistent with the principle
established by these workers (55). Furthermore, interference
with two-point MO adhesion to TSP provides an explanation
for the individual and synergistic inhibitory effects of mAbs to
CD36 and avf3 upon aged PMN ingestion. However, the data
appear to raise an interesting paradox. Whereas inhibition of
aged PMN ingestion occurs after blockade of either MO recep-
tor for TSP, such blockade does not inhibit MO adhesion to
TSP, which requires simultaneous blockade of both CD36 and
aCf33. A possible explanation is that the conformation of sub-
strate-bound TSP, as well as the substrate itself, may allow
more avid binding ofMO than the circumstances encountered
in TSP-mediated "bridging" to the apoptotic PMN. The result
would be that disruption of one receptor class is insufficient to
promote MO displacement from a TSP-coated substrate, while
it is adequate to prevent TSP-mediated phagocytosis of aged
PMN. It can be further speculated that a specific conformation
ofTSP presented by MO CD36 and af#3 is required for recogni-
tion and ingestion of apoptotic PMN. The candidate TSP epi-
topes binding to aCf33 and CD36 are thought to be located close
to the carboxyl terminus of each subunit of the trimeric mole-
cule ( 19, 20, 22), offering possibilities of dual receptor interac-
tion with a single TSP molecule. Further study will be needed
to define the stochiometry and precise molecular mechanisms
of interactions between aC#3,, CD36, and TSP occurring at the
MO surface during recognition of apoptotic PMNs.
It is important to consider how the proposed recognition
mechanism might operate at the inflamed site in vivo. The
potentiating effect of low concentrations of TSP suggests that
supply ofthis protein may be at a premium in our standard "no
added protein" interaction assay, but there is evidence that
TSP is in plentiful supply soon after injury of a tissue (35),
presumably being secreted by platelets and a range ofother cell
types. Indeed, the transient presence of the molecule in the
extracellular matrix of the healing skin wound corresponds
with the time PMNs are being removed from this and other
sites of self-limited inflammation (60). Although the Avf3 inte-
grin was originally thought to be specific for vitronectin ( 13,
61 ), this receptor has specificity for RGD-bearing proteins in
addition to TSP, namely Fn and fibrinogen (27, 62-65). Fn
has potential as a candidate for bridging aged PMN to MO,
since it may mediate agglutination of trypsinized erythrocytes
which can be inhibited by aminosugars and basic aminoacids,
and because both macrophages and neutrophils may synthe-
size the protein (66). However, by contrast with TSP, Fn did
not enhance recognition ofaged neutrophils by normal ( 12) or
cycloheximide-inhibited MO, nor did a mAb to the cell-bind-
ing domain of fibronectin inhibit recognition. Similarly, nei-
ther Vn nor fibrinogen potentiated the interaction ( 12). There-
fore, the in vitro data mitigate against a bridging role for ligands
ofthe avi3 other than TSP, and such a role also seems unlikely
on the grounds that these molecules do not interact with CD36
(28, 57). However, the data suggest the speculative possibility
that in addition to local changes in pH, or in concentrations of
charged molecules ( 15), soluble or matrix-bound Fn or Vn, or
proteolytic fragments of these molecules, may, in certain cir-
cumstances, inhibit aged PMN removal by interfering with
TSP binding to M4 a,33, thus favouring release ofPMN con-
tents from dying cells and persistence of tissue injury.
To conclude, human monocyte-derived macrophage recog-
nition ofaging neutrophils undergoing apoptosis involves hith-
erto unknown functions for TSP and the macrophage surface
molecule CD36. The data in this report indicate that TSP acts
as a molecular bridge between apoptotic neutrophil and macro-
phage. At the macrophage surface, the evidence suggests that
TSP forms an adhesive complex involving macrophage CD36
and the af33 integrin. Further study of the mechanisms by
which TSP binds to apoptotic neutrophils will provide a new
approach to the identification of the surface changes that occur
in apoptotic cells to lead to their recognition as "senescent-
self." This study also implies that proteins that are frequently
incorporated into the extracellular matrix at inflamed sites
may play an important role in regulation ofmacrophage recog-
nition of apoptotic neutrophils, a cellular interaction that has
potential to limit the toxic potential ofneutrophils in inflamma-
tion.
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